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Accumulating evidence suggests that, during trans-
lation, nascent chains can form specific interactions
with ribosomal exit tunnel to regulate translation and
promote initial folding events. The clinically impor-
tant macrolide antibiotics bind within the exit tunnel
and inhibit translation by preventing progression
of the nascent chain and inducing peptidyl-tRNA
drop-off. Here, we have synthesized amino acid–
and peptide-containing macrolides, which are used
to demonstrate that distinct amino acids and pep-
tides can establish interaction with components of
the ribosomal tunnel and enhance the ribosome-
binding and inhibitory properties of the macrolide
drugs, consistent with the concept that the exit
tunnel is not simply a Teflon-like channel. Surpris-
ingly, we find that macrolide antibiotics do not inhibit
translation of all nascent chains similarly, but rather
exhibit polypeptide-specific inhibitory effects, pro-
viding a change to our general mechanistic under-
standing of macrolide inhibition.
INTRODUCTION
The translational machinery represents one of the major targets
within the cell for antibiotics (reviewed by Spahn and Prescott,
1996; Wilson, 2009). The majority of antibiotics inhibit protein
synthesis by binding at the active centers on the ribosome; for
example, the tetracyclines and aminoglycosides (gentamicin)
bind within the decoding site on the small subunit, whereas the
phenylpropanoids (chloramphenicol) and oxazolidinones (line-
zolid) bind within the A-site of peptidyltransferase center (PTC)
to block peptide-bond formation. In contrast, the clinically
important class of macrolide antibiotics bind within the ribo-
somal exit tunnel, where they are thought to inhibit translation504 Chemistry & Biology 17, 504–514, May 28, 2010 ª2010 Elsevierby blocking elongation of the nascent polypeptide chain, which,
in turn, induces peptidyl-tRNA drop-off (Mankin, 2008; Poehls-
gaard and Douthwaite, 2003).
Macrolides are a diverse family of antibiotics that contain
a central 12–16-membered lactone ring to which various sugar
substituent’s are attached; for example, erythromycin has a
14-membered ring with C3 cladinose and C5 desosamine
sugars (Figure 1), whereas tylosin has a 16-membered ring with
a C5 mycaminose-mycarose disaccharide as well as a C23
mycinose (Figures 1 and 2). Crystal structures of macrolides
bound to the large ribosomal subunit reveal that the drugs bind
within the ribosomal exit tunnel adjacent to the peptidyltransfer-
ase center (Figures 2A and 2B) (Hansen et al., 2002; Schlu¨nzen
et al., 2001). Surprisingly, 16-membered macrolides that have a
C6 ethyl aldehyde (with the aldehyde functional group at C20),
such as tylosin (Figure 1), form a reversible covalent bond with
the N6 of adenine 2062 (A2062; Escherichia coli numbering
used throughout) of the 23S ribosomal RNA (Figure 2B) (Hansen
et al., 2002). The lactone rings of different macrolides are gener-
ally positioned in the tunnel with very similar orientations, such
that the C5 sugars extend up the tunnel toward the PTC (Hansen
et al., 2002; Poulsen et al., 2000; Schlu¨nzen et al., 2001; Wilson
et al., 2005) (Figure 2B). Consistently, macrolides such as eryth-
romycin with only a single C5 sugar allow synthesis of short
oligopeptides of six to eight amino acids before peptidyl-tRNA
drop-off occurs, whereas macrolides with C5 disaccharides,
such as tylosin, allow only two to four amino acids to be synthe-
sized (Tenson et al., 2003), and can even directly inhibit the pep-
tidyltransferase reaction (Karahalios et al., 2006).
It should be noted, however, that the length of the pep-
tide synthesized before peptidyl-tRNA drop-off appears to be
dependent on the sequence being translated (Tenson et al.,
2003). Translation of short nascent pentapeptides of defined
sequence can lead to dissociation of macrolide antibiotics from
the ribosome and thus confer macrolide resistance (Lovmar
et al., 2006; Tenson et al., 1996; Tenson and Mankin, 2001).
Moreover, different pentapeptide sequences can confer resis-
tance to distinct macrolide members, suggesting a direct and
discriminating interaction between the nascent chain and theLtd All rights reserved
Figure 1. Chemical Structures of Macrolide Antibiotics
Chemical structures of tylosin (Tyl), desmycosin (Des), OMT, erythromycin, and derivatives used in this study (1)–(12) are depicted.
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Macrolide Interaction with the Ribosomal Tunnelmacrolide (Tenson et al., 1997; Tripathi et al., 1998; Vimberg
et al., 2004). Inducible expression of some macrolide resistance
genes, such as the methyltransferase encoded by the ermC
gene, requires macrolide-dependent translational stalling during
the synthesis of an upstream leader peptide (Mayford andChemistry & Biology 17,Weisblum, 1989; Ramu et al., 2009; Vazquez-Laslop et al.,
2008). Mutations in the ErmC leader peptide as well as within
components of the ribosomal exit tunnel, namely A2062 of the
23S rRNA, have been identified that relieve the translational stall-
ing (Ramu et al., 2009; Vazquez-Laslop et al., 2008), suggestingFigure 2. Binding of Macrolide Antibiotics
Within the Ribosomal Tunnel
(A) Transverse section through the large subunit of
the ribosome to visualize the ribosomal exit tunnel.
The position of tylosin (red), P-site tRNA (orange),
and a mock polypeptide chain (yellow) are indi-
cated. CP, central protuberance; rRNA, gray and
ribosomal proteins (dark blue).
(B) Zoom in on the macrolide-binding site within
the ribosomal tunnel. Tylosin (pink) shown with
lactone ring, C23-mycinose, and C5-mycami-
nose-mycarose are labeled. The asterisk indicates
the carbinolamine bond that forms between tylo-
sin and the N6 of 23S rRNA nucleotide A2062,
whereas the arrow indicates the shift in A2062
seen upon ligand binding. The positions of
A- and P-site aminoacyl-tRNAs are shown in green
and orange, respectively.
504–514, May 28, 2010 ª2010 Elsevier Ltd All rights reserved 505
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Macrolide Interaction with the Ribosomal Tunnela complex interplay between the antibiotic, the tunnel, and the
nascent polypeptide chain.
Although the ribosomal tunnel has for many years been
thought of as a passive conduit for the nascent chain, accumu-
lating evidence indicates the existence of many specific leader
peptides that induce translational stalling by directly interacting
with the ribosomal tunnel, and in doing so regulate translation
of a downstream gene (Tenson and Ehrenberg, 2002). Indeed,
recent cryo-EM reconstructions directly visualize interaction
between the nascent polypeptide chain and components of
the ribosomal tunnel (Becker et al., 2009; Bhushan et al., 2010;
Seidelt et al., 2009). Moreover, interaction between the nascent
chain and tunnel has been proposed to play a more general role
in modulating translation rate (Lu and Deutsch, 2008; Seidelt
et al., 2009) as well as influencing initial protein folding events
(Bhushan et al., 2010; Kosolapov and Deutsch, 2009; Lu and
Deutsch, 2005a, 2005b; Woolhead et al., 2004).
Here, we demonstrate that abolishing the potential of tylosin to
form a covalent bond with A2062 of the ribosome dramatically
reduces the binding and inhibitory properties of the drug, but
that this can be reversed by the addition of amino acid and
peptide side chains that enable interaction to be reestablished
with the ribosomal exit tunnel. A number of the macrolide-
peptide compounds are even more potent inhibitors of transla-
tion than their parent compounds. Surprisingly, we find that
macrolides exhibit nascent chain-specific effects: 5-O-mycami-
nosyl-tylonolid (OMT), a precursor of tylosin, has excellent anti-
microbial activity and is a potent inhibitor of firefly luciferase
synthesis. In contrast, OMT is a very poor inhibitor of green
fluorescent protein synthesis and can even protect the transla-
tional apparatus from the inhibitory effects of other macrolides,
such as erythromycin and tylosin. Differential effects are also
observed for other macrolide antibiotics but are not seen for non-
macrolide antibiotics, such as tetracyclines and chlorampheni-
cols. Collectively, our results demonstrate the direct and specific
interaction between peptides and the ribosomal tunnel and
suggest that the inhibitory effect of macrolides is dependent
on the sequence of the nascent polypeptide chain being
translated.
RESULTS
Peptide Interaction with the Tunnel Compensates
for Loss of the Covalent Bond
To investigate the effect of the covalent linkage between the C6
ethyl aldehyde of tylosin and the N6 of A2062 of the 23S rRNA
(Figure 2B), we synthesized a reduced form of tylosin, (1)
Tyl-H2, where the C6 ethyl aldehyde is replaced by hydroxyethyl
group (Figure 1A). Binding of (1) Tyl-H2 to the ribosome was
monitored by competition with radiolabeled [14C]-erythromycin
(apparent Kd calculations in Table S1, available online, are based
on a 2 hr incubation; see Experimental Procedures). In the con-
trol experiment, we demonstrate that tylosin is an excellent
competitor, completely abolishing the binding of erythromycin
at0.1 mM (Figure 3A). In contrast, (1) Tyl-H2 was totally inactive,
and no significant loss in erythromycin binding was observed
with 1003 higher concentrations (10 mM) of the compound
(Figure 3A). These results support the importance of the carbi-
nolamine covalent linkage for efficient ribosome binding, in506 Chemistry & Biology 17, 504–514, May 28, 2010 ª2010 Elsevieragreement with previous findings that modification of the C20
aldehyde group leads to a 100-fold increase in the MIC value
for a variety of gram-positive bacteria (Kirst et al., 1988; Narandja
et al., 1994; Omura et al., 1982; Omura and Tishler, 1972).
Next, we synthesized a series of macrolide derivatives where
amino acids and peptides were attached to the C20 aldehyde
position to investigate whether amino acids can establish
defined interactions with the ribosomal exit tunnel. We reasoned
that if this is indeed the case, then the peptide-tunnel interac-
tions should improve the binding affinity of the compounds.
As can be seen in Figure 3A, the presence of Ala-Ala at the
C20 position to generate (2) Tyl-A2 dramatically improves the
ability of the compound to compete with erythromycin for ribo-
some binding. Similar results were also obtained when Ala-Ala
was attached to the C20 position of desmycosin, a degradation
product of tylosin differing by the absence of a C5 mycarose, to
generate (3) Des-A2 (Figure 3A). This finding suggests that,
indeed, the Ala-Ala peptides establish interaction with the tunnel
to improve the binding of the compounds compared with the Tyl-
H2; however, it should be noted that the Kd of (2) Tyl-A2 and (3)
Des-A2 (18 nM for both compounds) are still significantly worse
than their C6 ethyl aldehyde–containing parent compounds tylo-
sin (0.65 nM) and desmycosin (0.3 nM) (Table S1; Figure 3A).
To test the inhibitory activity of the compounds, we utilized an
E. coli lysate–based, in vitro, coupled transcription-translation
system (Dinos et al., 2004; Starosta et al., 2009), where the syn-
thesis of green fluorescent protein (GFP) was monitored by
directly measuring fluorescence (Figure 3B). Consistent with
the ribosome binding results, tylosin was found to be an excel-
lent inhibitor, with an IC50 of 0.25 mM and abolishing translation
at 1 mM (Figures 3B and 3C), whereas (1) Tyl-H2 had an IC50 >
103 higher (4 mM) (Table S1) and did not even completely abolish
translation at 25 mM (data not shown). (2) Tyl-A2 exhibited
improved inhibitory characteristics, with an IC50 of 0.5 mM—
only slightly worse than that of tylosin (Figure 3C; Table S1).
This contrasts with the binding assay results where (2) Tyl-A2
was a significantly worse competitor of erythromycin than tylosin
for ribosome binding (Figure 3A). A similar trend was observed
when comparing desmycosin with (3) Des-A2, in that (3) Des-
A2 was a slightly more effective inhibitor than desmycosin.
However, unlike (2) Tyl-A2, both desmycosin and (3) Des-A2
could not fully abolish translation even at high concentrations
(Figure 3C; Table S1).
We have previously determined a crystal structure of (2) Tyl-A2
bound to the Deinococcus radiodurans large ribosomal subunit
(Wilson et al., 2005), which shows that the lactone ring binds in
a similar position to that seen for tylosin (Hansen et al., 2002).
The C20 Ala-Ala peptide protrudes into a small alcove or pocket
within the tunnel wall, where it stacks against the base of A2062
(Figure 3E). The presence of the C20 Ala-Ala peptide on (2) Tyl-
A2 precludes formation of the carbinolamine bond with the N6
of A2062, and as a result A2062 is in a shifted position compared
to the tylosin-50S structure (Hansen et al., 2002) (Figure 3D).
Optimized Stacking Interactions with A2062
Improves Inhibition
On the basis of the structure of the (2) Tyl-A2 bound to the large
subunit, a series of novel C6 tylosin derivatives were synthesized
that can potentially form better stacking interactions with theLtd All rights reserved
Figure 3. Inhibitory Effect of Tylosin and Desmycosin Ala2 Derivatives
(A) The ability of tylosin (pink), Tyl-H2 (gray), desmycosin (Des, blue), (2) Tyl-A2, and (3) Des-A2 to compete with radiolabeled erythromycin for binding to E. coli
70S ribosomes was determined. The binding of erythromycin in the absence of competing ligand was assigned as 100%.
(B) The amount of GFP produced in an E. coli in vitro transcription-translation assay in the presence or absence of tylosin, (1) Tyl-H2 and (2) Tyl-A2, Des, and (3)
Des-A2 was determined by monitoring fluorescence of GFP. The fluorescence of GFP in the absence of antibiotic was assigned as 100%.
(C) Quantification of (B) with symbols and colors for each compound as in (A).
(D) The binding site of tylosin on theH.marismortui 50S subunit showing the formation of a covalent carbinolamine bond between the C6 ethyl-aldehyde of tylosin
(red) and the N6 of the base of A2062 of the 23S rRNA (Hansen et al., 2002).
(E) The binding site of (2) Tyl-A2 (green) on the D. radiodurans 50S subunit showing the stacking interaction between the Ala-Ala side chain of (2) Tyl-A2 and the
base of A2062 of the 23S rRNA (Wilson et al., 2005).
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groups that replace the Ala amino acids. Because base-stacking
between RNA nucleotides is an efficient and highly ubiquitous
interaction mode within RNA particles, the first compound, (4)
Tyl-U, was designed with an uridine (U) RNA nucleobase linked
to the lactone C6 carbon by a four-atom linker (Figure 1). In the
translation assay, (4) Tyl-U was still a worse inhibitor than (2)
Tyl-A2, but was superior to (1) Tyl-H2 (Figure 4A; Table S1).
In parallel, we investigated the effect of replacing the Ala-Ala
peptide with the amino acid tyrosine (Tyr) to generate the (5)
Tyl=Tyr derivative, which also utilizes a five-atom linker.
Although this compound had improved binding and inhibitory
activity with respect to (1) Tyl-H2, it was still significantly worse
than (2) Tyl-A2 (Figures 4A and 4B; Table S1). We rationalized
that the double bond in the linker may restrict the conformational
freedom of the side chain and therefore synthesized a second
compound (6) Tyl-Tyr with a fully saturated linker. In the transla-
tion assays, (6) Tyl-Tyr was a significantly better inhibitor than (5)
Tyl=Tyr and (2) Tyl-A2 (Figure 4B; Table S1), which was consis-
tent with the improved binding properties of (6) Tyl-Tyr (Fig-
ure 4A). What was curious was (6) Tyl-Tyr had an IC50 compa-
rable to that of tylosin (Figure 4B; Table S1), despite being lessChemistry & Biology 17,effective than tylosin at competing for ribosome binding with
erythromycin (Figure 3A).
In a separate approach, we also attached carnitine to the C20
position to generate (7) Tyl-Car (Figure 1). The positively charged
side chain improves the aqueous solubility, compared with tylo-
sin, but was also intended to improve interactions with the highly
electronegative cleft in the ribosomal tunnel. Indeed, (7) Tyl-Car
displayed binding (Kd, 0.6 nM) and inhibition (IC50, 0.3) properties
very similar to those of tylosin (Figures 4A and 4B; Table S1), sug-
gesting that, like (2) Tyl-A2, the side chain of (7) Tyl-Car estab-
lishes interaction with the ribosomal tunnel that compensate
for the loss of the carbinolamine bond. (7) Tyl-Car was modeled
in the tunnel with the constraint that the lactone ring and A2062
were positioned as in (2) Tyl-A2 structure (Wilson et al., 2005).
The most energetically favorable solution indicated that the
carnitine side chain adopted a conformation that establishes
stacking interactions with A2062 (Figure 4C).
Enhanced Tylosin Antibiotics That Utilize
Peptide-Tunnel Interaction
To further explore the stacking potential of the C20 side chains
with the nucleobase of A2062, we decided to introduce504–514, May 28, 2010 ª2010 Elsevier Ltd All rights reserved 507
Figure 4. Stacking Interaction with A2062
(A) The ability of tylosin, (1) Tyl-H2, (4) Tyl-U, (5) Tyl=Tyr, (6) Tyl-Tyr, and (7) Tyl-Car to compete with radiolabeled erythromycin for binding to D. radiodurans 70S
ribosomes was determined. The binding of erythromycin in the absence of competing ligand was assigned as 100%.
(B) Quantification of the fluorescence of GFP produced in an E. coli in vitro transcription-translation assay in the presence or absence of tylosin, (1) Tyl-H2, (4)
Tyl-U, (5) Tyl=Tyr, (6) Tyl-Tyr, and (7) Tyl-Car. The fluorescence of GFP in the absence of antibiotic was assigned as 100%.
(C) Model based on Tyl-A2 for the binding site of (7) Tyl-Car (yellow) on the D. radiodurans 50S subunit showing the stacking interaction between the carinitine
sidechain of (7) Tyl-Car and the base of A2062 of the 23S rRNA.
(D) The ability of tylosin, desmycosin (Des), OMT, (8) Tyl-Phe, (9) Des-Phe, and (10) OMT-Phe to compete with radiolabeled erythromycin for binding to
D. radiodurans 70S ribosomes was determined. The binding of erythromycin in the absence of competing ligand was assigned as 100%.
(E) Quantification of the fluorescence of GFP produced in an E. coli in vitro transcription-translation assay in the presence or absence of tylosin, desmycosin (Des),
OMT, (8) Tyl-Phe, (9) Des-Phe, and (10) OMT-Phe. The fluorescence of GFP in the absence of antibiotic was assigned as 100%.
(F) Model based on (2) Tyl-A2 for the binding site of (8) Tyl-Phe (purple) on theD. radiodurans 50S subunit showing the stacking interaction between the linker of (8)
Tyl-Phe and the base of A2062, as well as a between the phenylalanine aromatic residue and the base of C2586 of the 23S rRNA.
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maintaining its overall flexibility. Binding studies indicate that
this compound, (8) Tyl-Phe, improved the ribosome bind-
ing affinity (Kd, 3.6 nM) compared to (1) Tyl-H2 (Figure 4D;
Table S1). Consistently, (8) Tyl-Phe was found to be a very
potent inhibitor of translation (Figure 4E), performing slightly
better than tylosin but significantly better than (2) Tyl-A2 and
(1) Tyl-H2 (Table S1). The Phe side chain may stabilize the bind-
ing of (8) Tyl-Phe by establishing additional stacking interac-
tions with 23S rRNA nucleotides (Figure 4F). However, the
improved ribosome binding affinity cannot be the sole explana-
tion for the increased translational inhibitory activity relative to
tylosin, because (8) Tyl-Phe was significantly less effective
compared to tylosin at competing erythromycin from the ribo-
some (Figure 4D).508 Chemistry & Biology 17, 504–514, May 28, 2010 ª2010 ElsevierWe also synthesized (9) Des-Phe and (10) OMT-Phe, where the
Phe-containing linker side chain was attached to the C20 posi-
tion of desmycosin and OMT, respectively (Figure 1). OMT is
a precursor of tylosin, which lacks both the C5 mycarose and
the C23 mycinose (Figure 1). Our erythromycin competition
studies indicate that both (9) Des-Phe and (10) OMT-Phe were
worse competitors than their respective parent compounds (Fig-
ure 4D). The order of affinities of (8) Tyl-Phe > (9) Des-Phe > (10)
OMT-Phe is the same as for tylosin > desmycosin > OMT, and
correlates with the predicted surface areas that these
compounds bury on the ribosome; that is, more surface area
buried equals higher binding affinity (Hansen et al., 2002).
However, that each derivative had a lower binding affinity than
the parent compound emphasizes again the important influence
that the C6-ethyl aldehyde and presumably the carbinolamineLtd All rights reserved
Figure 5. Protective Effects of OMT
Compounds
(A) The ability of tylosin, OMT, (11) BocAAF-OMT,
and (12) fMLF-OMT to compete with radiolabeled
erythromycin for binding to D. radiodurans 70S
ribosomes was determined. The binding of eryth-
romycin in the absence of competing ligand was
assigned as 100%.
(B) Quantification of the fluorescence of GFP
produced in an E. coli in vitro transcription-transla-
tion assay in the presence or absence of tylosin,
OMT, (11) BocAAF-OMT, and (12) fMLF-OMT.
The fluorescence of GFP in the absence of antibi-
otic was assigned as 100%.
(C) Quantification of the fluorescence of GFP
produced in an E. coli in vitro transcription-transla-
tion assay in the presence of increasing concen-
trations (upper x-axis) of erythromycin (Ery) to
5 mM, then with additional presence of increasing
concentrations (lower x-axis) of OMT (cyan), (11)
BocAAF-OMT (magenta), (12) fMLF-OMT (blue),
or (10) OMT-Phe (yellow).
(D) Quantification of the fluorescence of GFP
produced in an E. coli in vitro transcription-transla-
tion assay in the presence of increasing concen-
trations (upper x-axis) of tylosin (Ery) to 5 mM,
then with additional presence of increasing con-
centrations (lower x-axis) of OMT (cyan), (11)
BocAAF-OMT (magenta), (12) fMLF-OMT (blue),
or (10) OMT-Phe (yellow).
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rolides on the ribosome.
In the translation system, (9) Des-Phe and (10) OMT-Phe, like
(8) Tyl-Phe, were more potent inhibitors than would have been
expected on the basis of their Kd values. (9) Des-Phe and (10)
OMT-Phe had IC50 values (0.1 mM and 0.3 mM, respectively)
similar to that of tylosin (0.25 mM) (Figure 4E; Table S1), thus indi-
cating that the presence of the peptide and its interaction with
the tunnel can compensate for loss in binding affinity resulting
from disruption of the covalent linkage with the ribosome. In
contrast, we found unexpectedly that desmycosin and OMT
were very poor inhibitors of translation. Even with high concen-
trations of antibiotic (50–100 mM), desmycosin never inhibited
translation by more than 50% (Figure 3B), and OMT had little
or no significant inhibitory effect (Figure 4E). This finding was
surprising because (1) both OMT and desmycosin bound effi-
ciently to an empty ribosome (Figure 4D), with Kd values of 3 nM
and 0.3 nM, respectively (Table S1), similar to that previously
reported (Karahalios et al., 2006) and that is 5- and 50-fold better
than that of erythromycin (Kd, 15 nM) (Karahalios et al., 2006);
and (2) both OMT and desmycosin have potent antimicrobial
activity (data not shown). Indeed, OMT and desmycosin are
known to have MIC values similar to tylosin for a number of
gram-positive bacterial strains (e.g., Streptococcus pyogenes,
Staphlococcus aureus, and Enterococcus faecalis) (Fu et al.,
2006; Kirst et al., 1988; Mutak et al., 2004).
Protective Effects of Peptide-OMT Precursor
Compounds Against Translation Inhibition
To investigate the differential effects of OMT in more detail,
we synthesized a series of peptide-OMT compounds, whereChemistry & Biology 17,BocAlaAlaPhe and fMetLeuPhe peptides were attached to
C14(C23) of OMT to generate (11) BocAAF-OMT and (12) fMLF-
OMT derivatives, respectively. These compounds still retain a C5
sugar and the C6 ethyl aldehyde, and the placement of the
peptide side chain on the C14(C23) position of the lactone ring
orients it such that it would penetrate deeper into the ribosomal
tunnel. Like OMT, both (11) BocAAF-OMT and (12) fMLF-OMT
were excellent competitors of erythromycin, although the pres-
ence of the peptide did not enhance the affinity of the derivative
for the ribosome (Figure 5A). In contrast, the presence of the
peptide improved the inhibitory effect of the OMT derivatives,
particularly, (12) fMLF-OMT, which inhibited the in vitro transla-
tion reaction by 50% at 1 mM (Figure 5B).
Because OMT and some of the derivatives were shown to bind
efficiently to an empty ribosome, but were poor inhibitors in the
translation assay, we decided to test whether the compounds
could relieve the translation inhibition effect that results from
other more effective macrolide antibiotics, such as tylosin and
erythromycin. Figure 5C shows that, at 5 mM erythromycin, the
translation of GFP is totally abolished, whereas when OMT,
(11) BocAAF-OMT, or (12) fMLF-OMT are additionally titrated
into the reaction, the inhibition of translation was gradually alle-
viated. As a control, (10) OMT-Phe, which was shown itself to
be a potent inhibitor (Figure 4E), could not relieve the inhibitory
effect due to erythromycin (Figure 5C). Indeed, the extent of relief
appeared to correlate inversely with the innate inhibitory activity
of the compound; for example, OMT and (11) BocAAF-OMT,
which were the poorest inhibitors, yielded the strongest relief
(up to 40% with 5 mM—that is, equimolar concentration to eryth-
romycin), whereas (12) fMLF-OMT, which was a slightly better
inhibitor, only restored translation by up to 20% at 5 mM final504–514, May 28, 2010 ª2010 Elsevier Ltd All rights reserved 509
Figure 6. Polypeptide Chain-Dependency of Macrolide Antibiotics
(A) Comparison of the effect of desmycosin (Des) and OMT on the in vitro transcription-translation of green fluorescent protein (GFP) and firefly luciferase (Fluc).
(B) Comparison of the effect of tylosin (Tyl) and erythromycin (Ery) on the in vitro transcription-translation of GFP and Fluc.
(C) Comparison of the effect of chloramphenicol (Cam) and tetracycline (Tet) on the in vitro transcription-translation of GFP and Fluc. In (A)–(C), the fluorescence of
GFP or luminescence of Fluc in the absence of antibiotic was assigned as 100%.
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prising, since at 5 mM of (12) fMLF-OMT, the drug itself reduces
translation by 60% (to 40%). Similar results were observed when
5 mM tylosin was used instead of erythromycin; however, higher
excesses of OMT and the derivatives were required to obtain the
equivalent inhibitory relief that was observed with erythromycin
(Figure 5D). For example, 10 mM (23 tylosin concentration) of
OMT produced only30% relief (Figure 5D). This trend is consis-
tent with the higher affinity and IC50 of tylosin over erythromycin
(Table S1) and thus supports the idea that the relief is due to
direct competition between the OMT/OMT-derivative and the
inhibitory compound (tylosin or erythromycin). Additional evi-
dence includes the observations that (1) OMT/OMT-derivatives
could not relieve the translation inhibition resulting from nonma-
crolide antibiotics, such as tetracycline or thiostrepton (data not
shown), and (2) compounds that were very poor competitors
with erythromycin, such as (1) Tyl-H2 (Figure 3A), produced
very low inhibition relief with extremely high excesses of com-
pound—for example, 25 mM (53 excess) (1) Tyl-H2 produced
4% relief for 5 mM tylosin (data not shown).
Macrolide Antibiotics Exhibit Polypeptide-Specific
Inhibitory Effects
Because of the inconsistency between the potent antimicrobial
activity of OMT and the poor inhibitory activity in the in vitro
translation assay, we decided to test whether OMT displayed
some template-specific effects. To do this, we substituted the
GFP template with firefly luciferase (Fluc) and monitored trans-
lation of Fluc using luminescence. Figure 6A shows that OMT
is an excellent inhibitor of translation of Fluc, with an IC50 of
0.15 mM, similar to that observed for the inhibition of GFP syn-
thesis by tylosin (0.25 mM). Similarly, we found that Des, which we
had shown to be a poor inhibitor of GFP (Figure 3C), was a potent
inhibitor of Fluc synthesis (Figure 6A). Less dramatic differences
were observed when comparing the effect of tylosin and erythro-
mycin on GFP and Fluc synthesis (Figure 6B). The effect of tylo-
sin on GFP and Fluc synthesis was similar, whereas the corre-
sponding values for erythromycin were 1 mM (GFP) and 0.75 mM
(Fluc) (Table S1). We believe that this template dependency in
inhibition is specific for the macrolide class of antibiotics,510 Chemistry & Biology 17, 504–514, May 28, 2010 ª2010 Elsevierbecause we do not find such distinct inhibitory effects when
examining the inhibition of other antibiotic classes, such as the
tetracyclines or phenylpropanoids (i.e., chloramphenicol) (Fig-
ure 6C). Tetracycline inhibits GFP synthesis with an IC50 of
11 mM and Fluc with an IC50 of 7 mM, and chloramphenicol
inhibits GFP and Fluc with the same IC50 of 1 mM (Figure 6C).
DISCUSSION
The surface of the exit tunnel is largely hydrophilic and has no
patches of hydrophobic surface large enough to form a sig-
nificant binding site for hydrophobic sequences in nascent
polypeptide chains (Nissen et al., 2000). Although this general
‘‘nonstick’’ characteristic of the exit tunnel may hold for the
majority of polypeptides being synthesized by the ribosome,
growing evidence indicates that particular nascent chain
sequences interact with the ribosomal tunnel during their egres-
sion (Becker et al., 2009; Bhushan et al., 2010; Cruz-Vera et al.,
2005; Cruz-Vera and Yanofsky, 2008; Gong and Yanofsky, 2002;
Kosolapov and Deutsch, 2009; Lawrence et al., 2008; Lu and
Deutsch, 2005a, 2005b, 2008; Nakatogawa and Ito, 2002; Seid-
elt et al., 2009; Tenson and Ehrenberg, 2002; Vazquez-Laslop
et al., 2008; Woolhead et al., 2004). Here, we have utilized mac-
rolide antibiotics to direct amino acid and peptide sequences to
bind and interact with the ribosomal tunnel. Our results indicate
that specific amino acid and peptide sequences can indeed
establish distinct interactions with components of the ribosomal
tunnel, such as stacking interactions between the backbone and
aromatic moieties with nucleotide A2062 of the 23S rRNA. A2062
is a universally conserved nucleotide that appears to adopt dif-
ferent conformations within the ribosomal tunnel dependent
upon the functional state of the ribosome. In the crystal structure
of the apo Haloarcula marismortui 50S subunit, A2062 lies flat
against the tunnel wall, whereas when P-site ligands are bound
A2062 shifts position to extend into the lumen of the ribosomal
tunnel (Figure 2B). It appears that A2062 also establishes inter-
action with the nascent polypeptide chains, as observed by
cryo-EM of stalled translating ribosomes (Bhushan et al., 2010;
Seidelt et al., 2009). Mutations of A2062 relieve the translational
arrest resulting during synthesis of the ErmC leader peptide,Ltd All rights reserved
Figure 7. Factors Influencing Macrolide Inhibition
(A) Schematic view of a transverse section through the large ribosomal subunit revealing a P-site tRNA (yellow) attached to a polypeptide chain (orange) in the
tunnel exit. The nucleotide A2062 (blue) has been proposed to interact with some polypeptide chains (Ramu et al., 2009; Vazquez-Laslop et al., 2008).
(B) Tylosin (red) binds within the tunnel where it forms a covalent bond with A2062 of the 23S rRNA and allows only translation of short peptides.
(C) Reducing the C6 ethylaldehyde of tylosin to produce (1) Tyl-H2 prevents the covalent interaction with A2062, reducing the binding affinity and allowing trans-
lation in the presence of the drug.
(D) Addition of amino acids or peptides to the C20 position prevents the covalent interaction with A2062, but establishes new compensatory interaction with the
tunnel that increases the binding affinity and thus allows only translation of short peptides.
(E) OMT (cyan) binds within the tunnel where it forms a covalent bond with A2062 of the 23S rRNA and allows only translation of short peptides of the Fluc protein.
(F) Translation of short pentapeptide sequences confers resistance to macrolide antibiotics, such as erythromycin (Tenson et al., 1996). The peptide is thought to
interact with the drug and remove it from the binding site when the peptide is released from the tRNA (Tenson and Mankin, 2001).
(G) Translation of GFP is not inhibited by OMT (cyan) either because the polypeptide chain removes the drug from its binding site or can pass the drug
undisturbed.
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the nascent chain as it passes through the tunnel (Figure 7A)
(Vazquez-Laslop et al., 2008).
A2062 is also involved in the interaction of 16-membered mac-
rolides, such as tylosin, with the ribosome because it forms
a covalent bond with the drug. Here we show that reducing the
C6-ethyl aldehyde of tylosin (Tyl-H2), which abolishes the poten-
tial to form a covalent linkage with the N6 of A2062, dramatically
reduces the Kd value by >100-fold (Table S1). The corresponding
loss in effectiveness of this antibiotic in translation inhibition is
seen by a reduction in IC50 by >10-fold (Table S1), suggesting
that the nascent polypeptide chain can now expel the drug
from the ribosome (Figure 7C). It should be noted, however,
that the presence of a C6-ethyl aldehyde is not strictly necessary
for efficient binding and potent inhibitory activity because eryth-
romycin has a C6-hydroxyl and thus cannot and does not form
the carbinolamine bond (Tu et al., 2005). The differences in orien-
tation (Hansen et al., 2002; Tu et al., 2005; Wilson et al., 2005)
and kinetics (Petropoulos et al., 2009) of binding between
14-membered macrolides, such as erythromycin, and 16-
membered macrolides, such as tylosin, seems to obviate the
C6-ethyl aldehyde in the former case. It would be interesting in
the future to analyze the characteristics of C6-ethyl aldehyde
containing 14-membered macrolides, with respect to bindingChemistry & Biology 17,modes, kinetics, and formation of the carbinolamine interaction
with A2062. Nevertheless, we could show that the loss of the
covalent bond can be compensated for by addition of amino
acid or peptide side chains to the C6(C23) position of the drug
(Figure 7D). On the basis of the observation that (2) Tyl-A2 stacks
upon the nucleobase of A2062 (Figures 3E and 7D), a series of
compounds was designed to explore different modes of interac-
tions with this region of the ribosome, culminating in a series of
compounds—(6) Tyl-Tyr, (7) Tyl-Car, (8) Tyl-Phe, (9) Des-Phe,
and (10) OMT-Phe—that were similar or better inhibitors of trans-
lation compared to tylosin (Figure 4; Table S1). These results also
demonstrate the potential to use the ribosome antibiotic struc-
tures as a basis for rational design of novel derivatives of antimi-
crobial agents.
One observation with respect to many of the macrolide-
peptide derivatives is the lack of correlation between the Kd
and IC50 values, namely that all of the macrolide-peptide deriva-
tives are less effective at competing erythromycin from the ribo-
some than are tylosin, but are relatively better inhibitors of trans-
lation. This suggests that the binding affinity per se does not
solely determine the effectiveness of the compound and that
the C20-side chains contribute an additional factor, perhaps by
sterically blocking the path of the nascent polypeptide chain
(Figure 7D). The most dramatic example of this is seen for504–514, May 28, 2010 ª2010 Elsevier Ltd All rights reserved 511
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lower than that of (10) OMT-Phe (Table S1), yet (10) OMT-Phe
is a vastly superior inhibitor of GFP synthesis (Figure 4E). The
ability of OMT and the peptide-OMT derivatives, (11) BocAAF-
OMT and (12) fMLF-OMT to restore translation in the presence
of inhibitory concentrations of erythromycin or tylosin (Figures
5C and 5D) is consistent with the binding data (Figures 4D and
5A), supporting the conclusion that these compounds do bind
to the ribosome, and thus are likely to reverse the effect of eryth-
romycin and tylosin by competing the drugs from their binding
site in tunnel.
The lack of effect of OMT on GFP synthesis (Figures 5E and
6A) was surprising because OMT is known to be a potent antimi-
crobial agent that targets the translation machinery (Fu et al.,
2006; Kirst et al., 1988; Mutak et al., 2004). This finding prompted
us to test the effect of macrolides on translation of Fluc, which
we could monitor using luminescence. OMT was found to be a
potent inhibitor of Fluc synthesis (Figure 7E), as was tylosin
(Figure 6A). Similarly, we found differential effects for desmyco-
sin, which was a poor inhibitor of GFP but an excellent inhibitor of
Fluc synthesis (Figure 6A). In contrast, few significant differences
were observed between the inhibition of GFP and Fluc synthesis
by other macrolides, such as tylosin (Figure 6B), erythromycin,
(Figure 6C), nor for other classes of antibiotics, such as chloram-
phenicols and tetracyclines (Figure 6C). We also generated
chimeric Fluc-GFP templates where the first 5–15 amino acids
of Fluc were placed at the N terminus of GFP and vice versa.
Unfortunately, the efficiency of translation of these proteins ap-
peared to be dramatically affected, such that the interpretation
of the results was inconclusive (data not shown).
Collectively, the data suggest that the sequence of the
nascent chain may influence the inhibitory ability of particular
macrolide antibiotics. Precedents for this include the observa-
tion that translation of specific pentapeptides can confer resis-
tance to macrolide antibiotics by chasing the drug from the ribo-
some (Figure 7F). Distinct pentapeptides sequences are specific
for particular macrolide or ketolide members, leading to the
proposal of a direct interaction between the nascent chain and
the drug in the ribosomal tunnel (Lovmar et al., 2006; Tenson
et al., 1996; Tenson and Mankin, 2001; Tenson et al., 1997;
Tripathi et al., 1998; Vimberg et al., 2004). By analogy, we
propose that the GFP nascent polypeptide chain establishes
specific interactions with OMT, leading to its removal from the
ribosome (Figure 7G).
Because macrolide antibiotics cannot bind to and inhibit
translating ribosomes (Contreras and Vazquez, 1977; Tai et al.,
1974), we do not believe that the differential inhibitory effects
of OMT on GFP and Fluc synthesis result from the ability of the
GFP, but not Fluc, nascent polypeptide chain to pass the drug
in the exit tunnel, but we cannot totally exclude this possibility.
Macrolide antibiotics have been shown to allow synthesis of up
to six to eight amino acids before peptidyl-tRNA drop-off occurs
(Tenson et al., 2003). This may hint that the N-terminal six to eight
residues of translating nascent chains, in this case GFP, inter-
acts with drug (OMT) and removes it from the tunnel by con-
tinued translation of the nascent chain (Figure 7G) as suggested
previously (Mankin, 2008), in contrast to drug removal via pep-
tidyl-tRNA hydrolysis, as occurs in the case of the macrolide-
resistance peptides (Figure 7F) (Tenson and Ehrenberg, 2002).512 Chemistry & Biology 17, 504–514, May 28, 2010 ª2010 ElsevierThe proposed model suggests that the translation of a particular
subset of proteins in vivo may not be inhibited by macrolide anti-
biotics, which could potentially provide the cell an additional
regulatory mechanism, for example, to up-regulate relevant
resistance genes. Future works needs to address the ubiquity
of this ‘‘translating nascent chain-mediated macrolide resis-
tance’’ and to determine whether specific consensus sequences
exist for distinct macrolides.EXPERIMENTAL PROCEDURES
Synthesis of Peptide Derivatives of Macrolides
(1) Tyl-H2 was prepared by reduction of Tyl with sodium borohydride (Kirst
et al., 1988). (2) Tyl-A2 and (3) Des-A2 were synthesized as described else-
where (Sumbatyan et al., 2003). (8) Tyl-Phe, (9) Des-Phe, and (10) OMT-Phe
were prepared by analogy with (2) Tyl-A2 and (3) Des-A2 (Sumbatyan et al.,
2003) by the condensation of 2-aminooxyacetylphenylalanyl ethyl ester with
Tyl (Des or OMT) in 0.4 M Na-acetate buffer (pH 4.7) at 50C (Sumbatyan
et al., 2010). (4) Tyl-U and (5) Tyl = Tyr were prepared by coupling of Tyl with
3-(uracyl-1-yl)alanine (or tyrosine) in methanol in the presence of sodium meth-
ylate at room temperature. (5) Tyl = Tyr was reduced with sodium borohydride
to give (6) Tyl-Tyr (Sumbatyan et al., 2010). The compounds were purified by
the column chromatography on silica gel, and their homogeneity and structure
were confirmed by TLC, HPLC, NMR, and mass spectra. BocAAF-OMT and
fMLF-OMT were synthesized as described elsewhere (Korshunova et al.,
2007). (7) Tyl-Car was synthesized starting from tylosin (24 mg, 0.026 mmol,
1 eq.) and carnitine hydrazide (Oka et al., 1963) (8 mg, 0.045 mmol, 1.7 eq.),
which were dissolved in Na-acetate buffer (pH 4.7) (1.5 ml), and the mixture
was stirred for 12 hr at 50C. The crude product was extracted with chloroform
and purified by silica gel column chromatography in chloroform-methanol (3:1,
v/v) system to give (7) Tyl-Car as white crystals: the yield, 42% (11.1 mg, 0.011
mmol); TLC: Rf (CHCl3 - CH3OH, 3:1) 0;7, Rf (CHCl3 - CH3OH – CH3COOH,
6:1:0.1) 0;25, Rf (CHCl3 - CH3OH, 6:1) 0;28, HPLC: tR = 19.7 min (gradient of
CH3CN in 0,1% CF3COOH 0%–60%); MALDI MS: m/z calculated. for
C53H93N4O18 1073.7; found 1070.6; NMR
1H (600 MHz, 303K, DMSO): 0.86
(3H, t, H17), 0.94 (3H, d, H18), 1.08 (3H, d, H5’’CH3), 1.15 (3H, s, H3’’CH3),
1.23 (3H, d, H21), 1.25 (3H, d, H50CH3), 1.28 (3H, d, H50’’CH3), 1.58 (1H, m,
H16), 1.65 (2H, m, H4, H2’’), 1.80 (3H, s, H22), 1.82 (4H, m, H7, H16, H2,’’
Ha Car), 1.90 (3H, m, H2, H7, H16), 1.95 (1H, m, H2), 2.48 (6H, 1H, s, m,
N(CH3)3, H3
0 ), 2.77 (2H, m, H6, H19), 2.88 (1H, m, H14), 2.98 (1H, dd, H20’’),
3.13 (m, 4H, H8, H40, H50), 3.38 (1H, m, H20), 3.39 (9H, s, N+(CH3)3
Car), 3.41
(2H, m, H5,’’ H3), 3.44 (3H, s, H20’’OCH3), 3.50 (3H, s, H30’’OCH3), 3.52 (3H,
m, Hg Car, H23), 3.61 (3H, m, H30’’, H5, H50’’), 3.80 (1H, m, H23), 4.12 (3H, m,
H10, H4,’’ Hb Car), 4.38 (1H, m, H40’’), 4.47 (1H, d, H10’’), 4.95 (3H, m, H15,
H1,’’ NHCar), 5.82 (1H, d, H13), 6.49 (1H, d, H10), 7.10 (1H, d, H11), 8.16
(1H, s, H20).
In Vitro Transcription-Translation Assay
All coupled transcription-translation experiments were performed using an
E. coli lysate–based system in the presence and absence of antibiotics, as
described elsewhere (Dinos et al., 2004; Starosta et al., 2009; Szaflarski
et al., 2008). Two microliters of each reaction was diluted with 50 mL of buffer
A (10 mM HEPES/KOH [pH 7.8], 10 mM MgCl2, 60 mM NH4Cl, and 4 mM
b-mercaptoethanol), mixed, and then transferred into black 96-well chimney
flat bottom microtiter plates. The GFP fluorescence was either on a Tecan
Infinite M1000 with an excitation wavelength of 395 nm and emission
509 nm, or measured at 520 nm (filter cutoff) with a Typhoon Scanner 9400
(Amersham Bioscience) using a Typhoon blue laser module (excited at
488 nm). Images were then quantified using ImageQuantTL (GE Healthcare)
and were represented graphical using SigmaPlot (Systat Software, Inc.).
Synthesis of firefly luciferase (Fluc) was performed as described above for
GFP, but using pIVEX-2.3MCS with Fluc cloned into the NdeI and SacI restric-
tion sites as a template. After incubation at 30C with shaking for 4–5 hr, 2 mL of
each reaction was added directly to white 96-well chimney flat bottom micro-
titer plates, after which 50 mL of luminol substrate (Promega) was quickly
added, shaken for 3 s, and the luminescence was immediately detected usingLtd All rights reserved
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had a standard deviation of less than 10%.
Binding Assay
Binding of all compounds to empty ribosomes was examined using a compe-
tition assay with radiolabeled [14C]Erythromycin (Perkin Elmer), as described
elsewhere (Karahalios et al., 2006; Petropoulos et al., 2009). Briefly, all
reactions contained 0.25 mM D. radiodurans 70S ribosomes and 1.25 mM
[14C]erythromycin in binding buffer (10 mM HEPES/KOH [pH 7.8], 30 mM
MgCl2, 150 mM NH4Cl, and 6 mM b-mercaptoethanol), which equated with
60% binding from the saturation curve (data not shown). The saturation curve
indicated that 80% of ribosomes were active (data not shown). To measure the
apparent Kd value for each of the compound, reactions were performed in the
absence or presence of increasing concentrations of the competing com-
pounds. After incubation at room temperature for 2 hr, reactions were passed
through nitrocellulose filters, type HA, 0.45 mm pore size (Millipore). Filters were
washed three times with binding buffer and then scintillation counted in the
presence of Filtersafe (Zinsser Analytic) scintillant. All measurements were
repeated in duplicate and had a standard deviation of 5%–10%.
Modeling and Figure Preparation
All chemical structures were drawn with ChemSketch and then were modified
with Adobe Illustrator. Small molecule structures for macrolide-peptide deriv-
atives were generated using ChemSketch. The lactone rings were then
replaced with the lactone ring from D. radiodurans 50S subunit in complex
with (2) Tyl-A2 (Wilson et al., 2005), and the derivative sidechains were
modeled on the basis of the position of the Ala-Ala sidechain of (2) Tyl-A2.
The models of the macrolide-peptide compounds in complex with the large
subunit were then minimized using CNS (Bru¨nger et al., 1998). All 3D structural
figures were produced using PyMol (http://www.pymol.org).
SUPPLEMENTAL INFORMATION
Supplemental information includes one table and can be found with this article
online at doi:10.1016/j.chembiol.2010.04.008.
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